Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Richter, 1928, Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia, Am J Pathol, 4, 285 Tsimberidou, 2005, Richter syndrome: biology, incidence, and therapeutic strategies, Cancer, 103, 216, 10.1002/cncr.20773 Tsimberidou, 2006, Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation, J Clin Oncol, 24, 2343, 10.1200/JCO.2005.05.0187 Velasquez, 1988, Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP), Blood, 71, 117, 10.1182/blood.V71.1.117.117 Press, 1991, Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation, J Clin Oncol, 9, 423, 10.1200/JCO.1991.9.3.423 Martelli, 1996, J Clin Oncol, 14, 534, 10.1200/JCO.1996.14.2.534 Philip, 1991, Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation, Blood, 77, 1587, 10.1182/blood.V77.7.1587.1587 Velasquez, 1994, ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study, J Clin Oncol, 12, 1169, 10.1200/JCO.1994.12.6.1169 Watts, 2000, ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients, Br J Cancer, 82, 278, 10.1054/bjoc.1999.0915 Ozturk, 2002, Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin, Chemotherapy, 48, 252, 10.1159/000066768 Kidani, 1980, Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers, Gann, 71, 637 Mathe, 1989, Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum, Biomed Pharmacother, 43, 237, 10.1016/0753-3322(89)90003-6 Chollet, 1996, Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer, Ann Oncol, 7, 1065, 10.1093/oxfordjournals.annonc.a010500 Wang, 1991, Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo, Leukemia, 5, 522 Yang, 1995, Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair, Mol Pharmacol, 47, 1072 Li, 1997, Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance, Mol Pharmacol, 52, 798, 10.1124/mol.52.5.798 Li, 1997, Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro, Cancer Res, 57, 1487 Gandhi, 1989, Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy, Blood, 74, 2070, 10.1182/blood.V74.6.2070.2070 Tsimberidou, 2008, Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia, J Clin Oncol, 26, 196, 10.1200/JCO.2007.11.8513 Moufarij, 2006, Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal, Blood, 108, 4187, 10.1182/blood-2006-05-023259 Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 Cheson, 1996, National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment, Blood, 87, 4990, 10.1182/blood.V87.12.4990.bloodjournal87124990 Tsimberidou, 2003, Cancer, 97, 1711, 10.1002/cncr.11238 Coiffier, 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 346, 235, 10.1056/NEJMoa011795 Badoux, 2011, Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia, Blood, 118, 2085, 10.1182/blood-2011-03-341032 Badoux, 2011, Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL, Blood, 117, 3016, 10.1182/blood-2010-08-304683